With over €4 billion in AUM, France’s Sofinnova closes Fund XI at €650 million to double down on MedTech magic

Paris-based VC company Sofinnova Partners has actually shut its newest front runner fund, Sofinnova Funding XI, at an excellent EUR650 million– a haul that exceeds its initial target and enhances its placement as a significant gamer in life scientific researches financial investment.

Support for the brand-new fund originated from a worldwide swimming pool of top-tier institutional financiers, consisting of sovereign riches funds, pharmaceutical titans, insurance policy companies, structures, and family members workplaces. Amongst the factors is the British Organization Financial institution, which verified a EUR30 million dedication to the fund. This financial investment is straightened with the UK federal government’s Life Sciences Industry Strategy.

Antoine Papiernik, Taking Care Of Companion and Chairman of Sofinnova Allies, claimed: “ This fundraising notes a zero hour for Sofinnova. It offers us the firepower to increase down on early-stage possibilities and enhances our distinctly joint, science-driven financial investment technique. We’re delighted to proceed backing visionary business owners and progressing the following wave of developments in scientific research and medication to bring them to individuals around the world“

In 2025, EU-Startups reported numerous noteworthy life-sciences and health-focused financing rounds throughout Europe, giving helpful context for Sofinnova Allies’ EUR650 million fund close.

France’s Adcytherix safeguarded EUR105 million to progress its antibody-drug-conjugate cancer cells treatment right into professional growth, while Sweden’s Cellcolabs increased EUR10.3 million to scale production of mesenchymal stem cells. In Switzerland, arcoris bio shut a EUR6.7 million Seed round to establish and commercialise its biomarker discovery modern technology.

Completely, these divulged rounds total up to approximately EUR121 million– considerable task at the start-up degree, yet still much listed below the range of Sofinnova’s recently shut lorry.

With an additional French business (Adcytherix) included amongst the current rounds, the information additionally indicates an especially energetic duration for French life-sciences development in 2025.

Papiernik included: “ Accomplishing this turning point in today’s unpredictable fundraising atmosphere speaks with the stamina of our design and the self-confidence our financiers remain to position in us.“

Established In 1972, Sofinnova Allies has actually taken a solid heritage over 5 years, with workplaces in Paris, London, and Milan, and a profile that extends greater than 500 business. With over EUR4 billion in AUM, the company is acknowledged for its science-driven financial investment technique and hands-on business developing throughout the life scientific researches worth chain.

The fund intends to power early-stage biopharmaceutical and MedTech start-ups dealing with unmet professional requirements throughout Europe and The United States and Canada, signalling an ongoing hunger for clinical development in tough times.

Sofinnova Funding XI is currently releasing resources right into pick business, proceeding the company’s energetic involvement in both preliminary and follow-on financing rounds. The fund’s emphasis lines up with its long-lasting goal to equate groundbreaking research study right into impactful treatments and innovations.

Mark Andrews, Financial Investment Supervisor, Finances, Life Sciences, British Organization Financial institution, claimed, “ Sofinnova is a principal in life scientific researches endeavor. Our dedication to them will certainly produce additional financial investment right into UK life scientific researches and aid strengthen the supervisor’s link to the UK. We delight in to officially invite Sofinnova to the Financial institution’s profile and eagerly anticipate seeing the developments that originate from this fund“

The launch of Sofinnova Funding XI better strengthens Sofinnova’s function as a foundation capitalist in early-stage BioTech and MedTech endeavors– simply this previous year, the overall resources increased throughout Sofinnova’s system has actually gotten to EUR1.5 billion.

With a fund dimension well over assumptions and ongoing global capitalist assistance, the company is positioned to increase clinical developments and industrial success for the future generation of medical care trendsetters.

Christine Hockley, Taking Care Of Supervisor and Co-Head of Finances, included: “ We are very energetic in the UK life scientific researches field, buying ingenious business both via funds and straight. We desire all high prospective business to be able to access the resources they require from preliminary development to complete growth and maturation. For that, we require extra funds with much deeper swimming pools of resources to be buying the UK and giving financing at the necessary development phase. Sofinnova Funding XI will certainly do precisely that“

The blog post With over €4 billion in AUM, France’s Sofinnova closes Fund XI at €650 million to double down on MedTech magic showed up initially on EU-Startups.